AAP
AMAG

Ardsley Advisory Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Ardsley Advisory Partners’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-205,000
Closed -$6.19M – 194
2015
Q4 		$6.19M Buy
+205,000
New +$6.62M 0.81% 39

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return

Ardsley Advisory Partners's AMAG Position: Q1 2016 in Review

Ardsley Advisory Partners sold out of AMAG Pharmaceuticals (AMAG) in Q1 2016, closing a stake of 205,000 shares — an estimated $6.19M sold.

Ardsley Advisory Partners first reported a position in AMAG in Q4 2015 and held it in 1 quarter. The position peaked at $6.19M in Q4 2015. 185 funds tracked by Wall St. Rank hold AMAG as of Q1 2016.

  • Ardsley Advisory Partners reported no remaining AMAG Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Ardsley Advisory Partners sold 205,000 AMAG Pharmaceuticals shares in Q1 2016, an estimated $6.19M.
  • Ardsley Advisory Partners first reported a position in AMAG Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Ardsley Advisory Partners's AMAG Pharmaceuticals position peaked at $6.19M in Q4 2015.
  • 185 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2016.

Based on Ardsley Advisory Partners's 13F filing for Q1 2016, filed 16 May 2016.